Cancer discovery
Molecular and immune correlates of response to first-line de-escalated chemotherapy plus penpulimab and anlotinib in advanced cervical cancer.
Qin Xu, Zhengrong Deng, Jing Liu, Yanhong Zhuo, Fei Zhu, Lele Chang, Qin Liu, Yajuan Fu, Peiwei Li, Yunyun Liu, Songhua Huang, Li Li, Xingyun Xie, Ying Chen, Yingtao Lin
Published: 202510.1158/2159-8290.CD-25-1315
Abstract
Standard of care for advanced cervical cancer includes chemotherapy, anti-angiogenic and/or immune checkpoint blockade regimens. Although effective, it leads to pleiotropic side effects. De-escalation chemotherapy together with immunotargeted therapi…
Preview only. Read the full abstract at the source